A comprehensive study on the review of virosomes  As a novel drug delivery system

Ramya Teja Medarametla; Venkata Gopaiah K; N Suresh Kumar J; Kumar Sai A; Mohana chari G; Kranti Kiran A; Koteswarao Naik B; Sandya rani K

doi:10.37022/jpmhs.v6i4.94

Authors

Ramya Teja Medarametla Associate Professor, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta. Palnadu (Dt), Andhra Pradesh, India – 522601
Dr. K. Venkata Gopaiah Associate Professor, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P
Dr. J.N Suresh Kumar Professor and Principal, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta. Palnadu (Dt), Andhra Pradesh, India – 522601
A. Kumar Sai Research Students, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P
G. Mohana chari Research Students, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P
A. Kranti Kiran Research Students, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P
B. Koteswarao Naik Research Students, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P
K. Sandya rani Research Students, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P

DOI:

https://doi.org/10.37022/jpmhs.v6i4.94

Keywords:

Virosome, Non-immunogenic, Glycoproteins, Haem Agglutinin

Abstract

Virosomes can be used as vaccines and vehicles for the cellular transport of various macromolecular molecules. The potential for drug delivery and targeting systems to be implemented using virosomes represents an exciting area of research. Virosomes are biocompatible, biodegradable, nontoxic, and nonimmunogenic, so efforts have been made to utilize them as anti-inflammatory or adjuvant agents, as well as drug and organic delivery frameworks for therapeutic applications. The success of virosomal drug delivery depends on the strategy used to assemble and fuse typeable bioactive materials into virosomes. Potential innovations of virosomes could be used to transport peptides and nucleic acids or qualities and drugs such as antitoxins, anticancer agents, and steroids.

Downloads

Download data is not yet available.

References

Manchester M, Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Advanced drug delivery reviews. 2006 Dec 1;58(14):1505-22.

Ramani K, Bora RS, Kumar M, Tyagi SK, Sarkar DP. Novel gene delivery to liver cells using engineered virosomes. FEBS letters. 1997 Mar 10;404(2-3):164-8.

Kapoor D, Vyas RB, Lad C, Patel M. A multipurpose and novel carrier for drug delivery and targeting-virosomes. Journal of drug delivery and therapeutics. 2013 Sep 14;3(5):143-7.

Almeida J, Edwards DC, Brand C, Heath T. Formation of virosomes from influenza subunits and liposomes. The Lancet. 1975 Nov 8;306(7941):899-901.

Cusi MG. Applications of influenza virosomes as a delivery system. Human vaccines. 2006 Jan 31;2(1):1-7.

Suarez DL, Schultz-Cherry S. Immunology of avian influenza virus: a review. Developmental & Comparative Immunology. 2000 Mar 1;24(2-3):269-83.

Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: the contributions of virus and host factors. Current opinion in immunology. 2011 Aug 1;23(4):481-6.

Liu H, Tu Z, Feng F, Shi H, Chen K, Xu X. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Acta pharmaceutica. 2015 Jun 30;65(2):105-16.

Shaikh SN, Raza S, Ansari MA, Khan GJ, Athar SH. Overview on virosomes as a novel carrier for drug delivery. Journal of drug delivery and therapeutics. 2018;8(6-s):429-34.

Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, Palache AM, Wilschut J. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine. 2003 Feb 14;21(9-10):925-31.

Singh N, Gautam SP, Kumari N, Kaur R, Kaur M. Virosomes as novel drug delivery system: an overview. PharmaTutor. 2017 Sep 1;5(9):47-55.

Kalra N, Dhanya V, Saini V, Jeyabalan G. Virosomes: as a drug delivery carrier. American Journal of Advanced Drug Delivery. 2013;1(1):29-35.

Shaikh SN, Raza S, Ansari MA, Khan GJ, Athar SH. Overview on virosomes as a novel carrier for drug delivery. Journal of drug delivery and therapeutics. 2018;8(6-s):429-34.

Nalawade R, Nalawade A, Patwa H, Ghode S, Raut R, Chatur VM. Virosomes: A Drug Carrier System. J Hosp Pharm. 2021;16(1):1-9.

Noda T, Kawaoka Y. Structure of influenza virus ribonucleoprotein complexes and their packaging into virions. Reviews in medical virology. 2010 Nov;20(6):380-91.

Waelti E, Wegmann N, Schwaninger R, Wetterwald A, Wingenfeld C, Rothen-Rutishauser B, Gimmi CD. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer research. 2002 Jan 15;62(2):437-44.

Stegmann T, Morselt HW, Booy FP, Van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. The EMBO journal. 1987 Sep;6(9):2651-9.

Bron R, Ortiz A, Wilschut J. Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry. 1994 Aug;33(31):9110-7.

Schoen P, Bron R, Wilschut J. Delivery of foreign substances to cells mediated by fusion-active reconstituted influenza virus envelopes (virosomes). Journal of Liposome Research. 1993 Jan 1;3(3):767-92.

Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science. 2001 Jul 13;293(5528):251-3.

Metsikkö K, van Meer G, Simons K. Reconstitution of the fusogenic activity of vesicular stomatitis virus. The EMBO Journal. 1986 Dec;5(13):3429-35.

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. The virosome concept for influenza vaccines. Vaccine. 2005 Jul 8;23:S26-38.

Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current opinion in biotechnology. 2004 Dec 1;15(6):518-29.

Singh N, Gautam SP, Kumari N, Kaur R, Kaur M. Virosomes as novel drug delivery system: an overview. PharmaTutor. 2017 Sep 1;5(9):47-55.

Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Advanced drug delivery reviews. 2000 Sep 30;43(2-3):197-205.

Moser C, Amacker M. Influenza virosomes as antigen delivery system. InNovel Immune Potentiators and Delivery Technologies for Next Generation Vaccines 2012 Nov 4 (pp. 287-307). Boston, MA: Springer US.

Koppers-Lalic D, Hogenboom MM, Middeldorp JM, Pegtel DM. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Advanced drug delivery reviews. 2013 Mar 1;65(3):348-56.

Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert review of vaccines. 2013 Jul 1;12(7):779-91.

Radha GV, Rani TS, Sarvani B. A review on proniosomal drug delivery system for targeted drug action. Journal of basic and clinical pharmacy. 2013 Mar;4(2):42.

Soussan E, Cassel S, Blanzat M, Rico‐Lattes I. Drug delivery by soft matter: matrix and vesicular carriers. AngewandteChemie International Edition. 2009 Jan 2;48(2):274-88.

Bhattacharya S, Mazumder B. Virosomes: A novel strategy for drug delivery and targeting. BioPharm International. 2011 Jan 2;2011(1).

Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, Palache AM, Wilschut J. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine. 2003 Feb 14;21(9-10):925-31.

Goyal AK, Khatri K, Mishra N, Vyas SP. New patents on mucosal delivery of vaccines. Expert opinion on therapeutic patents. 2008 Nov 1;18(11):1271-88.

Nordly P, Madsen HB, Nielsen HM, Foged C. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert opinion on drug delivery. 2009 Jul 1;6(7):657-72.

Miyanohara A. Preparation of vesicular stomatitis virus-G (VSV-G) conjugate and its use in gene transfer. Cold Spring Harbor Protocols. 2012 Apr 1;2012(4):453-6.

Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. Journal of hepatology. 2011 Jun 1;54(6):1273-85.

Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharmaceutical research. 2011 Feb;28:215-36.

Miller AA, Miller PF. Emerging trends in antibacterial discovery: answering the call to arms. (No Title). 2011.

Markovic I, Leikina E, Zhukovsky M, Zimmerberg J, Chernomordik LV. Synchronized activation and refolding of influenza hemagglutinin in multimeric fusion machines. The Journal of cell biology. 2001 Nov 26;155(5):833-44.

Muhammad A, Champeimont J, Mayr UB, Lubitz W, Kudela P. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert review of vaccines. 2012 Jan 1;11(1):97-116.

Kudela P, Koller VJ, Lubitz W. Bacterial ghosts (BGs)—advanced antigen and drug delivery system. Vaccine. 2010 Aug 16;28(36):5760-7.

Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert opinion on drug delivery. 2011 Apr 1;8(4):505-19.

Wilschut J. Influenza vaccines: the virosome concept. Immunology letters. 2009 Feb 21;122(2):118-21.

Joshi MD, Unger WJ, Storm G, Van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. Journal of Controlled Release. 2012 Jul 10;161(1):25-37.

Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Current opinion in immunology. 2012 Jun 1;24(3):310-5.

Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends in immunology. 2009 Jan 1;30(1):23-32.

O'Hagan DT, Wack A. Adjuvants: from serendipity to rational discovery. Vaccinology: Principles and Practice. 2012 Aug 3:348-60.

Zurbriggen R, Novak-Hofer I, Seelig A, Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Progress in Lipid Research. 2000 Jan 1;39(1):3-18.

Chen DL, Zheng D, Paller AS. Nano-based gene therapy for dermatologic diseases. InNanotechnology in Dermatology 2012 Sep 19 (pp. 109-117). New York, NY: Springer New York.

Markovic I, Leikina E, Zhukovsky M, Zimmerberg J, Chernomordik LV. Synchronized activation and refolding of influenza hemagglutinin in multimeric fusion machines. The Journal of cell biology. 2001 Nov 26;155(5):833-44.

Pastori C, Wahlestedt C. Involvement of long noncoding RNAs in diseases affecting the central nervous system. RNA biology. 2012 Jun 1;9(6):860-70.

Nardin E. The past decade in malaria synthetic peptide vaccine clinical trials. Human vaccines. 2010 Jan 1;6(1):27-38.

Sharma R, Yasir M. Virosomes: a novel carrier for drug delivery. Int J Pharm Tech Res. 2010;2(4):2327-39.

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. The virosome concept for influenza vaccines. Vaccine. 2005 Jul 8;23:S26-38.

Waelti E, Wegmann N, Schwaninger R, Wetterwald A, Wingenfeld C, Rothen-Rutishauser B, Gimmi CD. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer research. 2002 Jan 15;62(2):437-44.

De Jonge J, Holtrop M, Wilschut J, Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene therapy. 2006 Mar;13(5):400-11.

Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin PE, Donati M, Glück R. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology. 2000 Nov 10;277(1):111-8.

Dijkstra J, Bron R, Wilschut J, De Haan A, Ryan JL. Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes). Journal of immunology (Baltimore, Md.: 1950). 1996 Aug 1;157(3):1028-36.

Waelti ER, Glück R. Delivery to cancer cells of antisense L‐myc oligonucleotides incorporated in fusogenic, cationic‐lipid‐reconstituted influenza‐virus envelopes (cationic virosomes). International journal of cancer. 1998 Aug 31;77(5):728-33.

Pöltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Glück R, Pluschke G. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clinical & Experimental Immunology. 1999 Sep;117(3):496-503.